Cristin-resultat-ID: 1890945
Sist endret: 22. februar 2023, 12:59
Resultat
Fagartikkel
2020

Posttransplantation Lymphoproliferative Disease Treated by Retransplantation

Bidragsytere:
  • Ingerid Weum Abrahamsen
  • Bjørn Christer Grønvold
  • Else Marit Inderberg
  • Nadia Mensali
  • Jonas Mattsson og
  • Tobias Gedde-Dahl

Tidsskrift

Case Reports in Immunology
ISSN 2090-6609
e-ISSN 2090-6617
NVI-nivå 1

Om resultatet

Fagartikkel
Publiseringsår: 2020
Volum: 2020
Open Access

Importkilder

Scopus-ID: 2-s2.0-85147397087

Beskrivelse Beskrivelse

Tittel

Posttransplantation Lymphoproliferative Disease Treated by Retransplantation

Sammendrag

Epstein–Barr virus- (EBV-) induced posttransplantation lymphoproliferative disease (PTLD) is a life-threatening complication following allogeneic stem cell transplantation. *e main risk factor is anti-thymocyte globulin (ATG). Patients who fail first-line treatment with rituximab have a poor prognosis. *ough adoptive transfer of EBV-specific T cells is a potentially effective option, it is not readily available. In this case report, the patient developed PTLD following transplantation for aplastic anemia using ATG as part of the conditioning. He failed rituximab treatment and developed graft failure. We were aware that the stem cell donor had a recent EBV infection prior to transplantation, whereas the patient most likely was EBV negative before transplant. We describe our strategy to meet the patient’s urgent need for EBV-specific Tcells, as well as new hematopoietic stem cells. *e same donor was used for a second transplant, using peripheral blood stem cells. *e conditioning used was thiotepa/busulfan/fludarabin with a single dose of cyclophosphamide after transplant as graft-versus-host disease (GVHD) prophylaxis. *e EBV DNA levels fell when conditioning was started, and have been undetectable since day +15 and remained so till 18 months after transplantation. *e patient is doing well. *is case reports successful use of cyclophosphamide after transplantation as GVHD prophylaxis, preserving virus-specific immunity.

Bidragsytere

Ingerid Weum Abrahamsen

  • Tilknyttet:
    Forfatter
    ved Avdeling for blodsykdommer ved Oslo universitetssykehus HF

Bjørn Christer Linder Grønvold

Bidragsyterens navn vises på dette resultatet som Bjørn Christer Grønvold
  • Tilknyttet:
    Forfatter
    ved Avdeling for blodsykdommer ved Oslo universitetssykehus HF
  • Tilknyttet:
    Forfatter
    ved Avdeling for blodsykdommer ved Universitetet i Oslo
Inaktiv cristin-person

Else Marit Inderberg

Bidragsyterens navn vises på dette resultatet som Else Marit Inderberg
  • Tilknyttet:
    Forfatter
    ved Avdeling for kreftbehandling ved Oslo universitetssykehus HF

Nadia Mensali

  • Tilknyttet:
    Forfatter
    ved Seksjon for celleterapi ved Oslo universitetssykehus HF

Jonas Mattsson

  • Tilknyttet:
    Forfatter
    ved University of Toronto
  • Tilknyttet:
    Forfatter
    ved Universitetet i Oslo ved Universitetet i Oslo
1 - 5 av 6 | Neste | Siste »